High-affinity binding of β-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain

European Journal of Pharmacology

Volumn 518, Issue 2-3, 2005, Pages 234-242

  Miralles, Antonio ^a   Esteban, Susana ^a   Sastre Coll, Antonio ^a   Moranta, David ^a   Asensio, Víctor José ^a   García Sevilla, Jesús Andrés ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

carboline; (Rat) brain and liver; 3H 2 BFI; 3H Ro19 6327 (lazabemide); 3H Ro41 1049; Imidazoline I2 receptor; Morphine addiction; Norharman

Indexed keywords

BETA CARBOLINE; DOPA; HARMALINE; HARMALOL; HARMINE; IMIDAZOLINE I2 RECEPTOR; MONOAMINE OXIDASE A INHIBITOR; MORPHINE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; NALOXONE; OPIATE; TRYPTOLINE;

ANIMAL TISSUE; ARTICLE; ATTENUATION; BINDING AFFINITY; BRAIN CORTEX; CATALYSIS; CATALYST; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ANIMALS; BENZOFURANS; BINDING, COMPETITIVE; BRAIN; CARBOLINES; CEREBRAL CORTEX; DIHYDROXYPHENYLALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HARMINE; HIPPOCAMPUS; IMIDAZOLES; LIVER; MALE; MONOAMINE OXIDASE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NOREPINEPHRINE; PICOLINIC ACIDS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; SUBSTANCE WITHDRAWAL SYNDROME; THIAZOLES; TRITIUM; TYROSINE 3-MONOOXYGENASE;

EID: 23644460017     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.06.023     Document Type: Article

References (42)

1. 2 receptors, on glial fibrillary acidic protein concentration Eur. J. Pharmacol. 280 1995 205 210
2. 3H]2-(2-benzofuranyl)-2- imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes Naunyn-Schmiedeberg's Arch. Pharmacol. 356 1997 39 47
3. F. Aricioglu-Kartal, and I.T. Uzbay Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome Life Sci. 61 1997 1775 1781
4. F. Aricioglu-Kartal, H. Kayir, and I.T. Uzbay Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats Life Sci. 73 2003 2363 2371
5. F. Aricioglu, A. Means, and S. Regunathan Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system Eur. J. Pharmacol. 504 2004 191 197
6. 2-imidazoline ligands Br. J. Pharmacol. 125 1998 175 185
7. P. Bousquet, H. Greney, V. Bruban, S. Schann, J.D. Ehrhardt, L. Monassier, and J. Feldman I(1) imidazoline receptors involved in cardiovascular regulation: where are we and where are we going? Ann. N.Y. Acad. Sci. 1009 2003 228 233
8. 2 receptors in human postmortem frontal cortex Eur. J. Pharmacol. 423 2001 109 114
9. S. Cappendijk, D. Fekkes, and M. Dzoljic The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine Behav. Brain Res. 65 1994 117 119
10. A. Carlsson, J.N. Davies, W. Kehr, M. Lindqvist, and C.V. Atack Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase Naunyn-Schmiedeberg's Arch. Pharmacol. 275 1972 153 168
11. 2 sites J. Pharmacol. Exp. Ther. 272 1995 681 688
12. R.M. Eglen, A.L. Hudson, D.A. Kendall, D.J. Nutt, N.G. Morgan, V.G. Wilson, and M.P. Dillon "Seeing through a glass darky": casting light on imidazoline "I" sites Trends Pharmacol. Sci. 19 1998 381 390
13. D. Fekkes, and W.T. Bode Occurence and partition of the β-carboline norharman in rat organs Life Sci. 52 1993 2045 2054
14. 2-adrenoceptors in the rat brain: up-regulation of receptors associated with increased receptor appearance J. Neurochem. 64 1995 2590 2597
15. J.A. García-Sevilla, P.V. Escribá, and J. Guimón Imidazoline receptors and human brain disorders Ann. N.Y. Acad. Sci. 881 1999 392 409
16. 2 receptors: a structure-affinity investigation Bioorg. Med. Chem. Lett. 14 2004 999 1002
17. V. Glover, J. Liebowitz, I. Armando, and M. Sandler β-Carbolines as selective monoamine oxidase inhibitors: in vivo implications J. Neural Transm. 54 1982 209 218
18. A.L. Hudson, R. Gough, R. Tyacke, L. Lione, M. Lalies, J. Lewis, S. Husbands, P. Knight, F. Murray, P. Hutson, and D.J. Nutt Novel selective compounds for the investigation of imidazoline receptors Ann. N.Y. Acad. Sci. 881 1999 81 91
19. S.M. Husbands, R.A. Glennon, S. Gorgerat, R. Gough, R. Tyacke, J. Crosby, D.J. Nutt, J.W. Lewis, and A.L. Hudson β-carboline binding to imidazoline receptors Drug Alcohol Depend. 64 2001 203 208
20. M. Iurlo, G. Leone, B. Schilstrom, L. Linner, G. Nomikos, P. Hertel, B. Silvestrini, and H. Svensson Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition Psychopharmacology (Berl.) 159 2001 98 104
21. H. Kim, S. Sablin, and R. Ramsay Inhibition of monoamine oxidase A by β-carboline derivatives Arch. Biochem. Biophys. 337 1997 137 142
22. Y. Kolesnikov, S. Jain, and G.W. Pasternak Modulation of opioid analgesia by agmatine Eur. J. Pharmacol. 296 1996 17 22
23. 2 site-selective ligands Ann. N.Y. Acad. Sci. 881 1999 114 117
24. 2 receptors Eur. J. Pharmacol. 304 1996 221 229
25. 3H]RX821002 (2-methoxy idazoxan) in the human and rat brains J. Pharmacol. Exp. Ther. 264 1993 1187 1197
26. N.G. Morgan, and S.L.F. Chan Imidazoline binding sites in the endocrine pancreas: can they fulfill their potential as targets for the development of new insulin secretagogues? Curr. Pharm. Des. 7 2001 1413 1431
27. N.G. Morgan, E.J. Cooper, P.E. Squires, C.E. Hills, C.A. Parker, and A.L. Hudson Comparative effects of efaroxasn and β-carbolines on the secretory activity of rodent and human β cells Ann. N.Y. Acad. Sci. 1009 2003 167 174
28. H. Nissbrandt, G. Engberg, M. Wilkström, T. Magnusson, and A. Carlsson NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 338 1988 148 161
29. 3H]- idazoxan binding sites in the rat brain Br. J. Pharmacol. 108 1993 597 603
30. 2-imidazoline receptor subtypes Naunyn-Schmiedeberg's Arch. Pharmacol. 354 1996 709 716
31. 2-imidazoline receptors in rat liver Br. J. Pharmacol. 121 1997 901 912
32. 2 sites and monoamine oxidase Ann. N.Y. Acad. Sci. 1009 2003 353 356
33. 2-binding sites in rabbit brain membranes Br. J. Pharmacol. 127 1999 57 (abstract)
34. R. Raddatz, S.L. Savic, V. Bakthavachalam, J. Lesnick, J.R. Jasper, C.R. McGrath, A. Parini, and S.M. Lanier Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme J. Pharmacol. Exp. Ther. 292 2000 1135 1145
35. S. Regunathan, and D.J. Reis Imidazoline receptors and their endogenous ligands Annu. Rev. Pharmacol. 36 1996 511 544
36. 2-imidazoline-binding proteins using monoamine oxidase-deficient mouse models Mol. Pharmacol. 58 2000 1085 1090
37. E.S.J. Robinson, N.J. Anderson, J. Crosby, D.J. Nutt, and A.L. Hudson Endogenous β-carbolines as clonidine-displacing substances Ann. N.Y. Acad. Sci. 1009 2003 157 166
38. H. Rommelspacher, T. May, and B. Salewski Harman (1-methyl-beta- carboline) is a natural inhibitor of monoamine oxidase type A in rats Eur. J. Pharmacol. 252 1994 51 59
39. E. Ruiz-Durántez, M. Torrecilla, J. Pineda, and L. Ugedo Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons Br. J. Pharmacol. 138 2003 494 500
40. 2-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors Br. J. Pharmacol. 130 2000 146 152
41. 2- adrenoceptors regulating monoamine synthesis in the brain of morphine-dependent rats Naunyn-Schmiedeberg's Arch. Pharmacol. 365 2002 210 219
42. F. Tesson, C. Pripp-Buns, A. Lemoine, J.P. Pegorier, and A. Parini Subcellular distribution of imidazoline-guanidinium receptive site in human and rabbit liver. Major localization to the mitochondrial outer membrane J. Biol. Chem. 266 1991 155 160